Amphastar Pharmaceuticals (NASDAQ:AMPH) – Investment analysts at Piper Jaffray dropped their Q3 2018 earnings per share estimates for Amphastar Pharmaceuticals in a research report issued to clients and investors on Wednesday, May 9th. Piper Jaffray analyst D. Amsellem now forecasts that the company will earn $0.22 per share for the quarter, down from their prior forecast of $0.27. Piper Jaffray has a “Buy” rating and a $26.00 price objective on the stock. Piper Jaffray also issued estimates for Amphastar Pharmaceuticals’ Q4 2018 earnings at $0.31 EPS, Q1 2019 earnings at $0.27 EPS, Q2 2019 earnings at $0.29 EPS, Q3 2019 earnings at $0.31 EPS, Q4 2019 earnings at $0.30 EPS and FY2019 earnings at $1.18 EPS.
Other analysts have also recently issued research reports about the company. ValuEngine upgraded Amphastar Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Wednesday, May 2nd. Wells Fargo reiterated a “buy” rating on shares of Amphastar Pharmaceuticals in a research report on Wednesday, March 21st. Needham & Company LLC reiterated a “buy” rating and set a $24.00 price objective (up previously from $23.00) on shares of Amphastar Pharmaceuticals in a research report on Tuesday, March 13th. BidaskClub upgraded Amphastar Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, February 10th. Finally, Zacks Investment Research cut Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, March 13th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and four have issued a buy rating to the company’s stock. Amphastar Pharmaceuticals presently has an average rating of “Hold” and a consensus price target of $21.33.
Amphastar Pharmaceuticals opened at $14.91 on Monday, MarketBeat Ratings reports. The firm has a market cap of $905.49 million, a P/E ratio of 39.24, a PEG ratio of 1.38 and a beta of 1.42. The company has a debt-to-equity ratio of 0.12, a current ratio of 2.79 and a quick ratio of 1.85. Amphastar Pharmaceuticals has a one year low of $14.40 and a one year high of $20.45.
Amphastar Pharmaceuticals (NASDAQ:AMPH) last posted its quarterly earnings data on Wednesday, May 9th. The company reported ($0.05) EPS for the quarter, missing analysts’ consensus estimates of $0.08 by ($0.13). The firm had revenue of $58.40 million for the quarter, compared to analysts’ expectations of $60.75 million. Amphastar Pharmaceuticals had a negative net margin of 1.50% and a positive return on equity of 3.38%. The firm’s revenue was up 3.0% compared to the same quarter last year. During the same quarter last year, the company posted $0.09 EPS.
In other Amphastar Pharmaceuticals news, CFO William J. Peters sold 19,801 shares of the business’s stock in a transaction dated Tuesday, March 13th. The stock was sold at an average price of $20.10, for a total transaction of $398,000.10. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Richard K. Prins sold 16,598 shares of the business’s stock in a transaction dated Thursday, March 15th. The shares were sold at an average price of $19.90, for a total value of $330,300.20. Following the sale, the director now directly owns 45,442 shares of the company’s stock, valued at approximately $904,295.80. The disclosure for this sale can be found here. Insiders have sold 57,099 shares of company stock valued at $1,131,215 in the last three months. 31.50% of the stock is currently owned by corporate insiders.
A number of large investors have recently added to or reduced their stakes in the business. Dimensional Fund Advisors LP grew its holdings in Amphastar Pharmaceuticals by 3.3% during the first quarter. Dimensional Fund Advisors LP now owns 1,685,448 shares of the company’s stock valued at $31,602,000 after purchasing an additional 53,646 shares during the period. Geode Capital Management LLC grew its holdings in Amphastar Pharmaceuticals by 1.7% during the fourth quarter. Geode Capital Management LLC now owns 332,824 shares of the company’s stock valued at $6,403,000 after purchasing an additional 5,435 shares during the period. Millennium Management LLC grew its holdings in Amphastar Pharmaceuticals by 1,746.9% during the fourth quarter. Millennium Management LLC now owns 293,672 shares of the company’s stock valued at $5,650,000 after purchasing an additional 277,771 shares during the period. Cortina Asset Management LLC bought a new stake in Amphastar Pharmaceuticals during the first quarter valued at about $4,907,000. Finally, Fisher Asset Management LLC grew its holdings in Amphastar Pharmaceuticals by 8.1% during the fourth quarter. Fisher Asset Management LLC now owns 229,277 shares of the company’s stock valued at $4,411,000 after purchasing an additional 17,094 shares during the period. 44.43% of the stock is owned by institutional investors and hedge funds.
About Amphastar Pharmaceuticals
Amphastar Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States and internationally. It operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients.
Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.